Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies.

Animals Antibodies, Monoclonal/genetics,immunology,metabolism,pharmacology Antibodies, Monoclonal, Murine-Derived Antibody-Dependent Cell Cytotoxicity/genetics,immunology Antigens, CD20/immunology,metabolism Antineoplastic Agents/immunology,metabolism,pharmacology Complement Activation/drug effects,genetics,immunology Complement C1q/immunology,metabolism Drug Evaluation, Preclinical/methods Humans Immunoglobulin Constant Regions/genetics,immunology Lymphocyte Depletion/methods Mutation, Missense Protein Binding/genetics,immunology Receptors, IgG/genetics,immunology Rituximab

Antibodies, Monoclonal Antibodies, Monoclonal, Murine-Derived Antigens, CD20 Antineoplastic Agents FcgammaRIIIA protein, mouse Immunoglobulin Constant Regions Receptors, IgG Rituximab Complement C1q